XML 56 R21.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Lease Obligation | 12 Months Ended
--- | ---
Dec. 31, 2021
Leases [Abstract] |
Lease Obligation | 14. LEASE OBLIGATION In December 2018, the Company entered into an operating lease with Vertex Pharmaceuticals Inc. (“Vertex”) to lease approximately 13,170 square feet of office, laboratory and vivarium space at 50 Northern Ave, Boston, Massachusetts, expiring in December 2020. In July 2020, the Company extended the term of the lease through February 2021. On July 21, 2020, the Company entered into an operating lease agreement for 20,752 square feet of office, lab and animal care facility space located in Boston, Massachusetts for the Company’s corporate headquarters. The commencement date of the lease was February 19, 2021 and the lease term is 63 months. The lease provides a three-month free rent period, which commenced on the lease commencement date. The base rent at commencement is $145 thousand per month and escalates by 3% annually for total lease payments during the term of $9.3 million. The Company's lease agreement requires the Company to maintain a cash letter of credit to secure their obligations under the lease of $0.9 million. This balance is included in other assets on the accompanying consolidated balance sheets. The Company recognized a right of use asset of $7.5 million and an operating lease liability of $7.5 million upon the commencement of the lease. The components of the lease costs which are included in the consolidated statements of operations and comprehensive loss were as follows (in thousands):
|  | Year Ended December 31, |
|  | 2021 |  |  | 2020 |
Operating lease costs |  | $ | 1,693 |  |  | $ | 1,011 |
Variable lease costs |  |  | 479 |  |  |  | 706 |
Total lease costs |  | $ | 2,172 |  |  | $ | 1,717 |
Our variable lease cost primarily related to operating expenses, parking, taxes and insurance associated with our operating leases. Supplemental cash flow information relating to the Company’s leases were as follows (in thousands):
|  | December 31, |
|  | 2021 |  |  | 2020 |
Cash paid for amounts included in the measurement of lease liabilities (operating cash flows) |  | $ | 1,259 |  |  | $ | 1,025 |
The remaining lease terms and discount rates related to our leases were as follows:
|  | As of December 31,
|  | 2021 |  | 2020
Remaining lease term |  | 4.4 years |  | 0.2 years
Discount Rate |  | 7.7% |  | 8.0%
The future minimum lease payments for the Company’s operating lease as of December 31, 2021, were as follows (in thousands):
Fiscal Year |  | Operating Leases |
2022 |  | $ | 1,774 |
2023 |  |  | 1,827 |
2024 |  |  | 1,882 |
2025 |  |  | 1,938 |
2026 |  |  | 817 |
Thereafter |  |  | — |
Total minimum lease payments |  |  | 8,238 |
Less amounts representing interest or imputed interest |  |  | 1,251 |
Present value of lease liabilities |  | $ | 6,987 |

X
- References No definition available. + Details
Name: | us-gaap_LeasesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -URI http://asc.fasb.org/subtopic&trid=77888251 + Details
Name: | us-gaap_LesseeOperatingLeasesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration